Recombinant IgE (Tanezumab Biosimilar) antibody

Catalog No. ABIN7795148

This Humanized Monoclonal antibody specifically detects IgE (Tanezumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant IgE (Tanezumab Biosimilar) antibody (ABIN7795148)

Target: IgE (Tanezumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This IgE (Tanezumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-IgE (Tanezumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Tanezumab Biosimilar, Human NGF Monoclonal Antibody

Characteristics: What is tanezumab biosimilar research grade? Tanezumab is a humanized IgG2-kappa monoclonal antibody against nerve growth factor (NGF) as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. Tanezumab selectively targets, binds to, and inhibits NGF. Tanezumab acts in the periphery in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), and in studies to date, tanezumab has not demonstrated a risk of addiction, misuse or dependence. Tanezumab biosimilar uses the same protein sequences as the therapeutic antibody tanezumab.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human NGF

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for IgE (Tanezumab Biosimilar)

Target: IgE (Tanezumab Biosimilar)

Alternative Name: Tanezumab Biosimilar

Target Type: Biosimilar